KRISTI DUBEY: Open Payments
NPI 1992210686 · HARTFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,368 in 56 payments from 24 companies in 2025. Trend: 2023 $860 · 2024 $464 · 2025 $1,368
Food & beverage: $1,240Education: $128
| Company | Payments | Amount |
|---|---|---|
| Celgene Corporation | 12 | $187 |
| Incyte Corporation | 4 | $170 |
| Astellas Pharma US Inc | 5 | $125 |
| Novartis Pharmaceuticals Corporation | 3 | $99 |
| E.R. Squibb & Sons, L.L.C. | 4 | $91 |
| JAZZ PHARMACEUTICALS INC. | 3 | $75 |
| GENZYME CORPORATION | 3 | $69 |
| PUMA BIOTECHNOLOGY, INC. | 2 | $52 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $51 |
| Janssen Biotech, Inc. | 2 | $45 |
Products named: Padcev, REBLOZYL, Fabhalta, OPDUALAG, OPDIVO, SARCLISA, NERLYNX, ZIIHERA.
Industry payments across CT — which companies pay providers there.
